Human Genome: Journal Reviews Lupus Drug Endpoints Positively (Dow Jones)
NovaDel Article Published in Headache: The Journal of Head and Face Pain (Business Wire)
Perioperative Fluvastatin Cuts Cardiac Events In Vascular Surgery (Elsevier Medical News)
Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion (The Pink Sheet)
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization.
Dainippon, which is headquartered in Osaka, announced plans to acquire Sepracor for $23 per share on Sept. 3, one day after takeover speculation led to a run up in the Lunesta marketer’s stock and a midday halt in trading.
Prestige Brands Replaces CEO Due To Differences With Board (The Tan Sheet)
Prestige Brands Holdings’ second change in the CEO post in three years likely will not impede its business, although it may spark questions about the firm, a market analyst says.
The OTC drug and personal care product firm announced that Mark Pettie resigned Sept. 2 as president and CEO due to differences with the board.
FDA Official Explains Prasugrel Approval (MedPage Today)
Novartis Says Swine Flu Vaccine Works Quickly (MedPage Today)
Study finds potential way to make an AIDS vaccine (Reuters)
Shire’s new ADHD drug Intuniv approved in the USA (PharmaTimes)
Elan’s J&J link-up breaches Tysabri deal with Biogen – US judge (PharmaTimes)
Encouraging early results for Novartis swine flu vaccine (PharmaTimes)
SUBSCRIBE